Verekitug Phase Two Details Support Quarterly Asthma Dosing
Upstream Bio presented full Phase II VALIANT results showing that verekitug 100 mg every 12 weeks reduced annualized severe-asthma exacerbations by 56% versus placebo (p
Verekitug
Upstream Defines Verekitug Phase III Programs After FDA Meetings
Following end-of-Phase II meetings with FDA, Upstream Bio disclosed one placebo-controlled pivotal trial each in severe asthma and chronic rhinosinusitis with nasal polyps. Both will test verekitug 400 mg subcutaneously every 12 weeks in…
